PTC Therapeutics, Inc.
(NASDAQ : PTCT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading PTCT News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
-0.76%172.501.1%$711.75m
GILDGilead Sciences, Inc.
0.09%70.540.9%$695.99m
CELGCelgene Corporation
0.47%134.311.1%$649.60m
REGNRegeneron Pharmaceuticals, Inc.
-1.75%517.332.7%$572.31m
ALXNAlexion Pharmaceuticals, Inc.
-0.13%126.071.9%$521.18m
BIIBBiogen Inc.
-0.09%280.321.2%$500.23m
VRTXVertex Pharmaceuticals Incorporated
-1.50%133.501.9%$279.31m
INCYIncyte Corporation
0.48%136.282.6%$278.87m
CLVSClovis Oncology, Inc.
-1.84%95.0018.0%$249.90m
TSROTESARO, Inc.
-2.16%146.5314.7%$249.01m
ILMNIllumina, Inc.
1.25%185.283.5%$164.61m
BLUEBluebird Bio, Inc.
-5.49%112.0019.3%$162.00m
PBYIPuma Biotechnology, Inc.
1.22%87.5021.1%$145.68m
KITEKite Pharma, Inc.
7.09%100.6616.1%$139.56m
EXASExact Sciences Corporation
2.31%35.5126.3%$130.55m

Company Profile

PTC Therapeutics, Inc. engages in the discovery, development, and commercialization of orally administered, small molecule therapeutics targeting an area of RNA biology. Its preclinical and discovery programs are focused on the development of new treatments for multiple therapeutic areas, including neuromuscular disease, oncology and infectious disease. It product, candidate ataluren, is used for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. The company was founded by Allan S. Jacobson and Stuart W. Peltz on March 31, 1998 and is headquartered in South Plainfield, NJ.,005W47-E